Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Dolgin, E. Epic $12 billion deal and FDA's approval raise CAR-T to new heights. Nat Biotechnol 35, 891–892 (2017). https://doi.org/10.1038/nbt1017-891
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1017-891
- Springer Nature America, Inc.
This article is cited by
-
The global chimeric antigen receptor T (CAR-T) cell therapy patent landscape
Nature Biotechnology (2020)
-
Evolution of CAR T-cell immunotherapy in terms of patenting activity
Nature Biotechnology (2019)
-
Allogene and Celularity move CAR-T therapy off the shelf
Nature Biotechnology (2018)
-
Reframing cell therapy for cancer
Nature Chemical Biology (2018)
-
Public biotech in 2017—the numbers
Nature Biotechnology (2018)